Home » Stocks » AVXL

Anavex Life Sciences Corp. (AVXL)

Stock Price: $11.31 USD -0.26 (-2.25%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $11.40 +0.09 (0.80%) May 7, 7:06 PM
Market Cap 792.05M
Revenue (ttm) n/a
Net Income (ttm) -27.54M
Shares Out 64.30M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $11.31
Previous Close $11.57
Change ($) -0.26
Change (%) -2.25%
Day's Open 11.53
Day's Range 11.21 - 11.76
Day's Volume 466,847
52-Week Range 3.42 - 28.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

1 week ago - GlobeNewsWire

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Other stocks mentioned: AXSM, BIIB, JAZZ, SAVA
2 weeks ago - Zacks Investment Research

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

1 month ago - GlobeNewsWire

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

1 month ago - GlobeNewsWire

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

1 month ago - GlobeNewsWire

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

2 months ago - GlobeNewsWire

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Shopify & GoDaddy

Other stocks mentioned: DENN, NET, GDDY, SHOP
2 months ago - CNBC

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...

2 months ago - GlobeNewsWire

Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET

2 months ago - GlobeNewsWire

Conference Call and Webcast To be Held Thursday, February 11, 2021 4:30 pm Eastern Time Conference Call and Webcast To be Held Thursday, February 11, 2021 4:30 pm Eastern Time

3 months ago - GlobeNewsWire

Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Anavex Life Sciences (AVXL) stock is soaring higher Thursday on heavy trading despite a lack of news concerning the company. The post AVXL Stock: 6 Things for Investors to Know About Anavex Life Science...

3 months ago - InvestorPlace

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Other stocks mentioned: AXSM, HOLX, MRNA, NVAX, SAVA, VIVO, VXRT
3 months ago - Zacks Investment Research

Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear to have lit...

Other stocks mentioned: BHVN, BIIB, LLY, SAVA
3 months ago - Seeking Alpha

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...

4 months ago - GlobeNewsWire

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q4 2020 Results - Earnings Call Transcript

4 months ago - Seeking Alpha

Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET

4 months ago - GlobeNewsWire

Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time

4 months ago - GlobeNewsWire

NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...

4 months ago - GlobeNewsWire

The company reported positive results from a phase 2 clinical trial.

4 months ago - The Motley Fool

Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the fiscal yea...

Other stocks mentioned: MESO, BNTX, LLY, VTVT
4 months ago - Benzinga

Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I

4 months ago - GlobeNewsWire

Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Property Portfolio Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Property Portfolio

5 months ago - GlobeNewsWire

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge ...

5 months ago - Insider Monkey

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...

5 months ago - GlobeNewsWire

Statistically s ignificant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008)

6 months ago - GlobeNewsWire

Anavex (AVXL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

The biotech's drug appears to help patients with Parkinson's disease dementia.

6 months ago - The Motley Fool

C linically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis

6 months ago - GlobeNewsWire

Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger the disease.

7 months ago - Seeking Alpha

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics fo...

7 months ago - GlobeNewsWire

Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Globa...

8 months ago - GlobeNewsWire

NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

8 months ago - GlobeNewsWire

Anavex Life Sciences Corp. (AVXL) CEO Dr.

9 months ago - Seeking Alpha

Conference Call and Webcast Today at 11:00 a.m. ET Conference Call and Webcast Today at 11:00 a.m. ET

9 months ago - GlobeNewsWire

Compassionate Use Special Access Scheme Approval for Alzheimer’s Patients to Continue Treatment with ANAVEX®2-73 (blarcamesine) after Completing the 5-Year ANAVEX®2-73-003 Phase 2a Clinical Study Compas...

9 months ago - GlobeNewsWire

Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern Time Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern Time

9 months ago - GlobeNewsWire

Anavex Life Sciences is developing drugs for the treatment of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Rett Syndrome, fragile X, Angelman syndrome, and infantile spasms.

10 months ago - Seeking Alpha

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

10 months ago - GlobeNewsWire

NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

10 months ago - GlobeNewsWire

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

10 months ago - Zacks Investment Research

Is (AVXL) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

10 months ago - GlobeNewsWire

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10 months ago - Zacks Investment Research

NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

11 months ago - GlobeNewsWire

Is (AVXL) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Anavex Life Sciences.

11 months ago - Zacks Investment Research

NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

11 months ago - GlobeNewsWire

Anavex Life Sciences (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multip... [Read more...]

Industry
Biotechnology
CEO
Christopher Missling
Employees
20
Stock Exchange
NASDAQ
Ticker Symbol
AVXL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price forecast is 18.80, which is an increase of 66.22% from the latest price.

Price Target
$18.80
(66.22% upside)
Analyst Consensus: Strong Buy